Late entry of 10 year old constipation drug into domestic market

A Takeda Pharmaceutical’s chronic idiopathic constipation therapy is expected to land in Korea after the 10^th anniversary for its global approval.

On the 18^th, the Ministry of Food and Drug Safety(MFDS) announced ‘Lubiprostone Cap(global product name: Amitiza),’ a Takeda’s chronic constipation drug, was approved for its Phase 3 clinical trial in Korea.

The Amitiza’s late entry into the domest...